COVID-19 and/with dengue infection: A curse in an overburdened healthcare system

Panda, Prateek Kumar; Sharawat, Indar Kumar

doi:10.1177/0049475520975945

Cited by 10 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The herbal formulae most commonly used for the treatment of pediatric COVID-19 are armeniacae semen, but evidence regarding their benefit is still inconclusive. [ 76 77 78 79 80 ]…”

Section: Discussionmentioning

confidence: 99%

COVID-19 treatment in children

Panda

Sharawat

Vivekanand

et al. 2021

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

Background: Exact information about the efficacy of various medications proposed by regulatory bodies in children with COVID-19 is limited due to the lack of controlled trials in the existing literature. Methods: Different electronic databases (MEDLINE, EMBASE, Web of Science, COCHRANE CENTRAL, LitCovid, medRxiv, and bioRxiv) were searched for articles describing the management of COVID-19 cases in children with 18 shortlisted medications. Prospective/retrospective studies/case series (with at least 20 cases) reporting COVID-19 in patients aged ≤14 years were searched to collect information regarding clinical details and severity of participants, medications used, and outcome. The pooled estimate of these parameters across studies was performed using a random-effect or fixed-effect meta-analysis depending on the degree of heterogeneity. Results: From a total of 5794 records, 97 studies/case series (8243 patients) fulfilled the eligibility criteria and were included in this systematic review. A total of 21% children received at least one medication specifically used for COVID-19. While antivirals were used in 15.3% of children, remedesivir was the most commonly used antiviral drug in 6.2% of included children without many reports of serious adverse effects. There was a more prevalent use of anti-inflammatory medications including corticosteroids (27.8%, P = 0.01). Total 91% of severe cases described in literature in children received some anti-inflammatory medications. Among them, corticosteroids (17%) and Intravenous immune globulin (IVIG) (17.5%) were the most predominant followed by interferon (4.2%), tocilizumab (1.5%), and anakinra (0.8%). The most predominant therapy among multisystem inflammatory syndrome in children (MIS-C) cases were IVIG (81%), followed by aspirin (67%), corticosteroids (64%), inotropes (62%), and anticoagulation (56%, mostly low molecular weight heparin, LMWH). Overall mortality was only 1.3%, but when we analyzed separately including only cases with moderate and severe disease, the mortality rate was 4.6%. Conclusion: Among pharmacological modalities, anti-inflammatory agents like corticosteroids and antivirals like remdesivir have the most promising evidence for severe cases of pediatric COVID-19. Intravenous immunoglobulin and other anti-inflammatory/immunomodulatory agents like anakinra, aspirin, and anticoagulants have important therapeutic role in cases with MIS-C. Most of the mild cases recover with conservative treatment only.

show abstract

“…The herbal formulae most commonly used for the treatment of pediatric COVID-19 are armeniacae semen, but evidence regarding their benefit is still inconclusive. [ 76 77 78 79 80 ]…”

Section: Discussionmentioning

confidence: 99%

COVID-19 treatment in children

Panda

Sharawat

Vivekanand

et al. 2021

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

show abstract

“…In 2020, the first wave of COVID-19 hit these countries together with a hyperendemic outbreak of dengue, overburdening already crowded healthcare systems. [ [14] , [15] , [16] ] Additionally, an overlap of symptoms is common between these two diseases, such as fever, headache, and myalgia, as well as laboratory findings such as thrombocytopenia, leukopenia with lymphopenia, and elevated transaminases, leading to delay and misdiagnosis. [ [17] , [18] , [19] , [20] , [21] ]…”

Section: Introductionmentioning

confidence: 99%

Severe dengue in the intensive care unit

Tejo,

Hamasaki,

Menezes

et al. 2024

Journal of Intensive Medicine

View full text Add to dashboard Cite

“…2 Surveillance of co-circulation of SARS-CoV-2 and dengue virus (DENV) is important for public health because of the high transmissibility of the viruses and the ability of both to produce potentially fatal outcomes, especially in patients with comorbidities. 3 …”

Section: Introductionmentioning

confidence: 99%

Co-Infection between Dengue Virus and SARS-CoV-2 in Cali, Colombia

Agudelo-Rojas

Rebellón-Sánchez

Torres

et al. 2023

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

The co-occurrence of COVID-19 with endemic diseases is a public health concern that may affect patient prognosis and outcomes. The objective of this study was to describe the clinical characteristics of patients with dengue virus (DENV) and SARS-CoV-2 co-infections and compare their outcomes against those of COVID-19 patients without dengue. A cross-sectional study was conducted in patients with SARS-CoV-2 infection who attended a single center in Cali, Colombia, from March 2020 to March 2021. All patients who were tested by both real-time polymerase chain reaction for SARS-CoV-2 and IgM/NS1 for DENV were included. Dengue was diagnosed as having either an IgM- or an NS1- positive test. A total of 90 patients were included (72 with COVID-19 only and 18 with co-infection). Patients with co-infection had more dyspnea (61.1% versus 22.2%; P = 0.003) as well as higher oxygen desaturation (53.3% versus 13.4%; P = 0.002) and neutrophil-to-lymphocyte ratio (5.59 versus 3.84; P = 0.038) than patients with COVID-19 alone. The proportion of patients classified with moderate to severe COVID-19 was higher in the co-infection group (88.3% versus 47.8%; P = 0.002). Also, co-infection was associated with an increased need for mechanical ventilation (P = 0.06), intensive care unit (ICU) initial management (P = 0.02), and ICU admission during hospitalization (P = 0.04) compared with COVID-19 only. The ICU mortality rate was 66.6% in patients with co-infection versus 29.4% in patients infected with only SARS-CoV-2 (P < 0.05). The possibility of DENV and SARS-CoV2 co-infection occurred in the convergence of both epidemic waves. Co-infection was associated with worse clinical outcomes and higher mortality in ICU-admitted patients than in patients with the COVID-19 only.

show abstract

COVID-19 and/with dengue infection: A curse in an overburdened healthcare system

Cited by 10 publications

References 20 publications

COVID-19 treatment in children

COVID-19 treatment in children

Severe dengue in the intensive care unit

Co-Infection between Dengue Virus and SARS-CoV-2 in Cali, Colombia

Contact Info

Product

Resources

About